홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Rivastigmine

HCID 77991
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
123441-03-2
표준 SMILES
CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1
InChIKey
XSVMFMHYUFZWBK-NSHDSACASA-N
분자식
C14H22N2O2
평균 분자량
250.34 g/mol
단동위원소 질량
250.16812795

개요

Rivastigmine is a carbamate ester obtained by formal condensation of the carboxy group of ethyl(methyl)carbamic acid with the phenolic OH group of 3-[(1S)-1-(dimethylamino)ethyl]phenol. A reversible cholinesterase inhibitor. It has a role as an EC 3.1.1.8 (cholinesterase) inhibitor, a cholinergic drug and a neuroprotective agent. It is a carbamate ester and a tertiary amino compound. It is a conjugate base of a rivastigmine(1+).

이름 및 식별자

우선 이름
Rivastigmine
IUPAC
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
영어명
Rivastigmine
분자식
C14H22N2O2
분자량
250.34

이름 및 동의어

rivastigmine123441-03-2PrometaxENA 713 free baseNimvastidRivastigmine Tevarivastigmine hexalRivastigminaRivastigmine sandozSDZ-ENA-713Rivastigmine Transdermal SystemSDZ-212-713
이름 더 보기
RIVASTIGMINE HYDROGEN TARTRATEmineEXELONRivastigmine baseRivastigKabaratincabalatineRevastigmineRivastigiMine
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamatem-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamateONO-2540PKI06M3IW0SDZ 212-713ENA-713D3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamateSDZ-212713

데이터베이스 식별자

CAS
123441-03-2
PubChem CID
77991
DTXSID
DTXSID7023564
ChEMBL
CHEMBL636
ChEBI
CHEBI:8874
UNII
PKI06M3IW0
EC Number
602-936-0

물성

구조 계산 물성

XLogP
2.3
극성 표면적
32.8 Ų
수소 결합 공여자 수
0
수소 결합 수용자 수
3
회전 가능 결합 수
5
무거운 원자 수
18
형식 전하
0
복잡도
269

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Acetylcholinesterase inhibitor

LogP2.3
Solubility2.04e+00 g/L
Human Drugs · 6건

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Physical DescriptionSolid
Dissociation Constants · 2건

8.8

8.99

Collision Cross Section165 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

물리화학적 성질

끓는 점
316.2 · 316.2±34.0 °C(Predicted)
밀도
1.038 · 1.038±0.06 g/cm3(Predicted)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 5건

This chemical does not meet GHS hazard criteria for 6.2% (1 of 16) of reports.

Danger

H300 (31.2%): Fatal if swallowed [Danger Acute toxicity, oral]

P261, P264, P270, P271, P273, P280, P301+P316, P302+P352, P304+P340, P317, P321, P330, P362+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 16 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 2 (31.2%)

독성 정보

Hepatotoxicity · 1건

In large placebo controlled trials, rivastigmine therapy was not associated with an increased rate of serum enzyme elevations compared to placebo treatment and no instances of clinically apparent liver injury with jaundice were reported. Nevertheless, since its introduction into clinical use, rivastigmine (administered by transdermal patch) has been implicated in at least one report of clinically apparent hepatotoxicity with mild jaundice. The time to onset was 2 months and the serum enzyme elevations had a mildly hepatocellular pattern. Mild rash and eosinophilia were also present, but autoimmune features were not. Recovery was complete within 5 weeks of drug discontinuation.

Adverse Effects · 1건

Adverse effects of rivastigmine have received thorough study as it has been on the market for some time. The main adverse effects associated with the use of rivastigmine are gastrointestinal. The primary symptoms are nausea and vomiting. These acute effects primarily occur during the initial dose-escalation phase of therapy with upward dose titration of the drug to achieve a therapeutic dose. These events can be minimized using a slow titration schedule and taking the medication with food if prescribing an oral formulation. In a study done to analyze the safety and tolerability of cholinesterase inhibitors used to treat Alzheimer dementia, researchers found rivastigmine to be the drug to have the highest rate of gastrointestinal side effects.

화학 및 산업

약리 정보

ATC Code · 3건

N06DA03

N - Nervous system

QN - Nervous system

Protein Binding40%
Pharmacodynamics · 1건

Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.

Mechanism of Action · 1건

Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.

Biological Half-Life1.5 hours
Metabolism/MetabolitesRivastigmine is rapidly metabolized by cholinesterase-mediated hydrolysis.
FDA Pharmacological Classification · 6건

PKI06M3IW0

RIVASTIGMINE

관련 반응

3건
반응 기록 만들기
HRID 532100 반응식
HRID 532100생성물로
HRID 907502 반응식
HRID 907502반응물로
HRID 1425636 반응식
HRID 1425636생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
Nikkaji
J982.502I
인화점
145 ℃ · 145℃
저장 조건
-20 °C · Sealed in dry,Store in freezer, under -20°C
용해도
클로로포름(적게), 에틸아세테이트(약간)에 용해됨
물리적 상태
가루
산도 계수 (pKa)
8.99 · pKa 8.99 (Uncertain)
색상
Colorless to light yellow
주요 응용
의약품(소분자)
InChI
InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
InChIKey
XSVMFMHYUFZWBK-NSHDSACASA-N
SMILES
C(OC1=CC=CC([C@@H](N(C)C)C)=C1)(=O)N(CC)C
Toxicity Summary · 1건

Toxicity to the drug, while rare, should be carefully monitored. Common toxicity manifestations include severe gastrointestinal reactions, allergic cutaneous reactions, and central nervous system effects. All cutaneous reactions due to usage of the patch should prompt immediate removal of the patch for at least 48 hours before reapplying in a new area. Therapy should be discontinued if symptoms last longer than 48 hours or a severe cutaneous reaction occurs.

Drug Induced Liver Injury · 5건

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

rivastigmine

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

안전 데이터

wgk
WGK 3
ridadr
UN 2810 6.1 / PGIII
HS 번호
2924296000
Hazard Classifications
Acute Tox. 2 OralAquatic Chronic 2
스토리지 클래스
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials

Established Pharmacologic Class [EPC] - Cholinesterase Inhibitor

Mechanisms of Action [MoA] - Cholinesterase Inhibitors

Rivastigmine is a Cholinesterase Inhibitor. The mechanism of action of rivastigmine is as a Cholinesterase Inhibitor.

RIVASTIGMINE

MeSH Pharmacological Classification · 2건

Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.

Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.

Absorption, Distribution and Excretion · 3건

Rivastigmine is extensively metabolized primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite NAP226-90. Renal excretion of the metabolites is the major route of elimination. Less than 1% of the administered dose is excreted in the feces.

1.8 to 2.7 L/kg

renal cl=2.1-2.8 L/hr

Cellular LocationsCytoplasm

용도 및 제조

UsesUse (kg; approx.) in Germany (2009): >100
응용 분야 · 3건

역사Rivastigmine was discovered by Marta Weinstock-Rosin of the Department of Pharmacology at the Hebrew University of Jerusalem and sold to Novartis by Yissum for commercial development. Rivastigmine, sold under the brand name Exelon among others, is an acetylcholinesterase inhibitor used for the treatment of dementia associated with Alzheimer's disease and with Parkinson's disease.

용도Antidepressant

일반 설명Rivastigmine (Exelon, EA 713) is apseudoirreversible noncompetitive carbamate inhibitor ofAChE. Although the half-life is approximately 2 hours,the inhibitory properties of this agent last for 10 hours becauseof the slow dissociation of the drug from the enzyme.The Food and Drug Administration (FDA) approved its usein mild-to-moderate Alzheimer disease in April 2000. InJuly 2007, rivastigmine was granted approval for use inmanaging mild-to-moderate dementia associated withParkinson disease.

상·하류 제품 정보

상류 원료

(S)-1-(3-(ethyl(methyl)carbamoyloxy)phenyl)-N,N-dimethyl-N-((S)-1-phenylethyl)ethanaminium iodideRivastigmine hydrochlorideCarbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-aminoethyl]phenyl ester1257519-35-9Methanamine, N-(benzoyloxy)-N-methyl-3-(1-(디메틸아미노)에틸]페놀3-[(1S)-1-(디메틸아미노에틸)]페놀에틸메틸-카르밤산염화물리바스티그민EP불순물E3-(1-hydroxyethyl)phenyl ethyl(methyl)carbamate(R)-3-(1-hydroxyethyl)phenylethyl(methyl)carbamate

추가 설명

정의ChEBI: A carbamate ester obtained by formal condensation of the carboxy group of ethyl(methyl)carbamic acid with the phenolic OH group of 3-[(1S)-1-(dimethylamino)ethyl]phenol. A reversible cholinesterase inhibitor.